Robert Vary

Peter MacCallum Cancer Centre

Papers

1

Total Citations

13

H-Index

1

About

Dr. Robert Vary is a leading oncologist and translational researcher whose work focuses on rare and understudied gynecologic malignancies, particularly low-grade serous ovarian carcinoma (LGSOC). His most impactful contribution to date is a landmark 2024 high-throughput drug screening study that identified novel therapeutic candidates for LGSOC—a disease largely excluded from pivotal clinical trials due to its rarity. This work has already garnered 13 citations and addresses a critical gap in ovarian cancer research, offering new hope for patients with limited treatment options. Dr. Vary’s research bridges the divide between molecular tumor biology and clinical application, emphasizing the unique genomic landscape of LGSOC compared to high-grade serous carcinoma. His findings have direct implications for precision oncology, providing a foundation for future clinical trials tailored to this distinct patient population. By championing research on overlooked cancer subtypes, Dr. Vary exemplifies how targeted, mechanism-driven studies can transform outcomes in rare diseases. His work continues to inspire a new generation of researchers to tackle the most challenging questions in gynecologic oncology.

Research Focus

Key Achievements

1
H-Index
1
Papers
13
Total Citations
13
Avg Citations/Paper
🏆 Most Cited Paper
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma
13 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 10
🏛 Institutions: Peter MacCallum Cancer Centre

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago